Sanofi Consumer Healthcare India Ltd
Sanofi Consumer Healthcare India Ltd Live Price Chart
Performance
| Previous Close | ₹ 4713.3 |
| High | ₹ 4731.2 |
| Volume | 1330 |
| 52W Range | ₹ 3975 - ₹ 5894.5 |
| Open | ₹ 4718.8 |
| Low | ₹ 4704.2 |
| Market Cap | ₹ 10755 Cr |
Sanofi Consumer Healthcare India Ltd Technicals
| 20 Day | ₹ 4,693.891 |
| 50 Day | ₹ 4,627.110 |
| 100 Day | ₹ 4,573.650 |
| 200 Day | ₹ 4,613.704 |
| 20 Day | ₹ 4,711.003 |
| 50 Day | ₹ 4,638.744 |
| 100 Day | ₹ 4,433.089 |
| 200 Day | ₹ 4,619.284 |
Sanofi Consumer Healthcare India Ltd Fundamentals
| ROCE | 75.604 |
| P/E Ratio | 42.030 |
| P/B Ratio | 28.230 |
| Industry P/E | 28.230 |
| Debt to Equity | 44.960 |
| ROE | 62.526 |
| EPS | 111.980 |
| Dividend Yield | 1.590 |
| Book Value | 166.748 |
| Face Value | 10.000 |
Sanofi Consumer Healthcare India Ltd Financials
| Particulars | Y202512 | Y202412 | Y202312 |
|---|---|---|---|
| Total Revenue | 896.8 | 737.5 | 559.5 |
| Total Expenses | 583.1 | 462.3 | 338.4 |
| Profit After Tax | 240.1 | 181 | 164.9 |
Sanofi Consumer Healthcare India Ltd Shareholding Pattern
| Promoter Holdings | 71.271 % |
| FIIs | 2.760 % |
| DIIs | 3.938 % |
| MutualFund | 13.630 % |
| Retail | 6.263 % |
| Others - | 2.139 % |
About Sanofi Consumer Healthcare India Ltd
Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business. This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity. The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024. In terms of said Scheme, the Company allotted 23,030,622 Equity Shares to the eligible shareholders of Sanofi India Limited (SIL) upon the demerger process. The demerger was strategically undertaken to facilitate independent and focused management for both businesses, enhance operational efficiency, provide greater transparency for stakeholders, and unlock shareholder value. The effective date of the Scheme was June 1, 2023. As per the Scheme, eligible shareholders of SIL received one fully paid-up equity share of the Company for every share they held in SIL on June 13, 2024. The Clayton, Dubilier & Rice group (CD&R Group) acquired majority control over Opal Bidco SAS and, ha ...
